Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: Implications for other countries

Applied Health Economics and Health Policy

Volumn 11, Issue 6, 2013, Pages 677-685

  Hesse, Ulrik ^a   Godman, Brian ^b,c,d   Petzold, Max ^e   Martin, Andrew ^f   Malmström, Rickard E ^b  

^a National Institute for Health Data and Disease Control   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f NHS Greater Manchester Commissioning Support Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; LOSARTAN;

ARTICLE; COST CONTROL; DENMARK; DRUG COST; DRUG UTILIZATION; HEALTH CARE POLICY; HUMAN; REIMBURSEMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; DENMARK; DRUG COSTS; DRUG UTILIZATION REVIEW; DRUGS, GENERIC; EUROPE; HEART FAILURE; HUMANS; HYPERTENSION; LOSARTAN; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; REIMBURSEMENT MECHANISMS; RETROSPECTIVE STUDIES;

EID: 84890526873     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0059-4     Document Type: Article

References (62)

1. Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl Health Econ Health Policy. 2010;8:7-24.
2. Godman B, Wettermark B, Hoffman M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9:65-83.
3. Godman B, Abuelkhair M, Vitry A, et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GABI. 2012;1(2):69-83.
4. Godman B, Bennie M, Baumgärtel C, et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia Health Econ Ther Pathways. 2012;13(Suppl 3):5-20.
5. OECD. "Pharmaceutical expenditure", in OECD. Health at a Glance 2011: OECD indicators. OECD Publishing (2011). doi: 10.1787/health-glance-2011- 63-en. Available from: http://www.oecd-ilibrary.org/docserver/download/fulltext/ 8111101ec063.pdf?expires=1343281688&id=id&accname=guest&checksum= 4D4F46B30255998AA81601571E18EE8F (Accessed 5 Aug 2013).
6. Garattini S, Bertele V, Godman B, et al. Enhancing the rational use of new medicines across European healthcare systems: a position paper. Eur J Clin Pharmacol. 2008;64:1137-8.
7. Garuoliene K, Godman B, Gulbinovič J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11:343-9.
8. Vončina L, Strizrep T, Godman B, et al. Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011;11:469-79.
9. Godman B, Malmstrom RE, Bennie M, Sakshaug S, Burkhardt T, et al. Prescribing restrictions: a necessary strategy among some European countries to enhance future prescribing efficiency? Rev Health Care. 2012;3:5-16.
10. Kalaba M, Godman B, Vuksanovic A, et al. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history? J Comp Eff Res. 2012;1:539-49.
11. Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol. 2011;1(141):1-16. doi: 10.3389/fphar.2010.00141.
12. Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10:707-22.
13. Godman B, Buscics A, Burkhardt T, et al. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries. Expert Rev Pharmacoecon Outcomes Res. 2010;10:199-207.
14. Wettermark B, Godman B, Neovius M, et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy. 2010;94:221-9.
15. Godman B, Haycox A, Schwabe U, et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics. 2008;26:91-8.
16. Mancia G, Laurent S, Agabiti R, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-58.
17. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2004;27:S65-7.
18. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.
19. Frisk P, Mellgren T-O, Hedberg N, et al. Utilisation of angiotensin blockers in Sweden combining survey and register data to study adherence to prescribing guidelines. Eur J Clin Pharmacol. 2008;64:1223-9.
20. Dickstein K, Cohen-Solal A, Filippatos G, on behalf of the task force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388-442.
21. Moon J, Flett A, Godman B, et al. Getting better value from the NHS drug budget. BMJ. 2011;342:30-2.
22. Gradman A, Papademetriou V. Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. Am Heart J. 2009;157:S17-23.
23. Mielniczuk L, Stevenson L. Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in the management of congestive heart failure patients: what have we learnt from recent clinical trials. Curr Opin Cardiol. 2005;20:250-5.
24. Fletcher A, Palmer A, Bulpitt C. Coughing with angiotensin converting enzyme inhibitors: how much of a problem? J Hypertens. 1994;12:S43-7.
25. NHS. PCT prescribing report. Prescribing of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-II receptor antagonists (AIIRAs): prescribing guidance and discussion points (2009). Available from: http://www.nhsbsa.nhs.uk/ Documents/PPDPCTReports/pctreport-20092.pdf (Accessed 2 March 2013).
26. Norman C, Zarrinkoub R, Hasselström J, et al. Potential savings without compromising the quality of care. Int J Clin Pract. 2009;63:1320-6.
27. Gustafsson LL, Wettermark B, Godman B, et al. The "Wise List" - a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108:224-33.
28. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract. 2008;62:480-4.
29. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2008;(4):CD003822.
30. NICE updates its guidance on the management of hypertension. MeReC 10 October 2011. Available from: http://www.npc.nhs.uk/rapidreview/?p=4470 (Accessed 3 March 2013).
31. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840-8.
32. Svanström H, Pasternak B, Hviid A. Association of treatment with losartan vs. candersartan and mortality among patients with heart failure. JAMA. 2012;307:1506-12.
33. Krum H. Optimising management of chronic heart failure. Lancet. 2009;374:1808-9.
34. National Prescribing Centre (NPC). Key therapeutic targets: medicines management options for local implementation (2011). Available from: http://www.npc.nhs.uk/qipp/resources/qipp-key-therapeutic-topics-july11- version3.1.v2.pdf (Accessed 3 March 2013).
35. MeReC. Key therapeutic targets; medicines management options for local implementation (2012). Available from: http://www.npc.nhs.uk/qipp/resources/Key- therapeutic-topics-Medicines-Management-for-local%20implementation-feb%202012- final.pdf (Accessed 3 February 2013).
36. Statens Serum Institut. Available from: http://www.medstat.dk/en (Accessed Aug 2013).
37. Bucsics A, Godman B, Burkhardt T, et al. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilisation patterns in Austria: implications for other countries. Expert Rev Pharmacoecon Outcomes Res. 2012;12:809-19.
38. Simoens S, De Bruyn K, Miranda J, Bennie M, Malmström RE, Godman B. Measures to enhance ARB prescribing efficiency in Belgium following generic losartan: impact and implications for the future. J Pharm Health Serv Res. 2013;4:173-81.
39. Godman B, Wettermark B, Miranda J, et al. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan: findings and implications for other countries. Int J Clin Pract. 2013. doi: 10.1111/ijcp.12130.
40. Godman B, Bennett K, Bennie M, et al. Variable approaches to enhancing the prescribing of losartan once generics available: influence and future direction. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 3):295.
41. Godman B, Martin A, Tilstone J, Saleem N. Pharmacists appreciably improving sartan prescribing efficiency in the UK: implications for other classes and countries. Pharmacoepidemiol Drug Saf. 2013;. doi: 10.1002/pds.3428.
42. Simoens S. A review of generic medicine pricing in Europe. GaBI. 2012;1(1):8-12.
43. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries - an overview. GaBI. 2012;1(2):93-100.
44. Dylst P, Vulto A, Godman B, Simoens S. Generic medicines: solutions for a sustainable drug market? Appl Health Econ Health Policy. 2013;. doi: 10.1007/s40258-013-0043-z.
45. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2011. WHO, Oslo (2010). Available from: http://www.whocc.no/atc-ddd-index/ (Accessed 5 Aug 2013).
46. Wagner A, Soumerai S, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299-309.
47. World Health Organization (WHO). Introduction to drug utilisation research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330). Available from: http://www.who.int/ medicines/areas/quality-safety/safety-efficacy/Drug%20utilization%20research. pdf (Accessed 5 Dec 2012).
48. Rønning M, Blix HS, Harbø BT, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose: are drug utilisation data comparable? Eur J Clin Pharmacol. 2000;56:723-7.
49. Vlahovic-Palcevski V, Gantumur M, Radosevic N, et al. Coping with changes in defined daily dose in longitudinal drug consumption databases. Pharm World Sci. 2010;32:125-9.
50. Atella V, Schafheutle E, Noyce P, Hassell K. Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and UK. Appl Health Econ Health Policy. 2005;4:23-35.
51. Andersson K, Sonesson C, Petzold M, et al. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 2005;14:341-8.
52. Godman B, Shrank W, Wettermark B, et al. Use of generics: a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals. 2010;3:2470-94. doi: 10.3390/ph/3082470ISSN1424-8247.
53. Vrijens F, Van de Voorde C, Farfan-Portet M-I, Stichle RV. Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data. Eur J Health Econ. 2012;13:315-25.
54. Wladysiuk M, Araszkiewicz A, Godman B, et al. Patient co-payments do influence atypical antipsychotic choice in Poland: implications once generic atypicals are available. Appl Health Econ Health Policy. 2011;9:101-10.
55. Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics. 2009;27:435-8.
56. Bennie M, Bishop I, Godman B, et al. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland? Qual Prim Care. 2013;21:7-15.
57. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012;12:125-30.
58. Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ. 1998;317:465-8.
59. Barton S. Using clinical evidence. BMJ. 2001;322:503-4.
60. Godman B, Bishop I, Finlayson AE, Campbell S, Kwon H-Y, Bennie M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):469-82.
61. Cramer JA, Benedict A, Muszabek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62:76-87.
62. Regional Drugs and Therapeutic Centre (NHS). Fixed-dose combinations (part 2): use in specific medical conditions (2008). Available from: http://www.nyrdtc.nhs.uk/docs/dud/DU-62-Fixed-Dose-Combinations-(2).pdf (Accessed 3 March 2013).